

COFFIN et al.  
Serial No. Unknown

**REMARKS**


The above amendments are made to place the claims in a more traditional format.

Attached hereto is a marked up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version with Markings to Show Changes Made**".

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By:



B. J. Sadoff

Reg. No. 36,663

**BJS:Imy**

1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

VERSION WITH MARKINGS TO SHOW CHANGES MADE

5. (Amended) A process according to [any one of the preceding claims] claim 1 wherein the control sequence comprises a constitutively active promoter or an inducible promoter.

6. (Amended) A process according to [any one of the preceding claims] claim 1 wherein the mutant herpes virus is a herpes simplex virus (HSV).

8. (Amended) A process according to [any one of the preceding claims] claim 1 wherein the mutant herpes virus comprises additional mutations which functionally inactivate one or more additional endogenous genes of said virus and the cell line comprises additional nucleic acid sequences encoding functional herpes virus genes which complement said additional functionally inactive endogenous genes.

11. (Amended) A process according to [any one of the preceding claims] claim 1 further comprising isolating mutant herpes virus from the cultured cell line, and optionally purifying the mutant herpes virus.

22. (Amended) A cell line according to claim 19[, 20 or 21] wherein the control sequence comprises a constitutively active promoter or an inducible promoter.

23. (Amended) A cell line according to [any one of claims 19 to 22] claim 19 wherein the cell line comprises additional nucleic acid sequences encoding functional herpes virus genes which complement said additional functionally inactive endogenous genes.

26. (Amended) A virus obtained by a process according to [any one of claims 1 to 11] claim 1.